Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb). Individuals with VHL disease often develop various manifestations, including cerebellar and spinal hemangioblastomas. Upon diagnosis, typically in their teens, patients undergo regular screening studies, including brain imaging. If these screenings detect the development of hemangioblastomas, closer monitoring is implemented. Historically, surgical intervention was the primary approach when lesions appeared threatening. However, the advent of HIF-2α inhibitors now offers an alternative, as these inhibitors can decrease the growth or even shrink the lesions. The overall approach involves early identification of VHL disease, consistent monitoring with imaging, and timely intervention with surgery or HIF-2α inhibitors as appropriate. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
